Last €65.86 EUR
Change Today +0.21 / 0.32%
Volume 453.0
NOTA On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 8:27 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by NOVARTIS AG-ADR (NOTA) in the last 6 months

Announced 04/22/14
5.35B for Novartis Animal Health Inc.
Merger/Acquisition

Elanco Animal Health, Inc entered into an agreement to acquire the assets of Novartis Animal Health Inc. from Novartis AG (SWX:NOVN) for approximately $5.4 billion in cash on April 22, 2014. The consideration is subject to working capital and other adjustments. Eli Lilly, the parent company of Elanco Animal Health plans to fund this acquisition with approximately $3.4 billion of cash-on-hand and $2 billion in debt to be issued. Novartis Animal Health Inc. reported revenues ...
Read More


NOTA's price was unchanged after the transaction was announced on 04/22/14.
Investor / Buyer
Elanco Animal Health, Inc.
Creditor / Lender
Novartis AG
Financial Advisor
The Goldman Sachs Group, Inc.
Legal Advisor
Freshfields Bruckhaus Deringer LLP
 
Announced 04/22/14
16.00B for GlaxoSmithKline plc, Marketed Oncology Portfolio, Related R&D Activities and AKT Inhibitor
Merger/Acquisition

Novartis AG (SWX:NOVN) entered into an agreement to acquire marketed oncology portfolio, related R&D activities and AKT inhibitor from GlaxoSmithKline plc (LSE:GSK) for $16 billion in cash on April 22, 2014. The consideration amount is subject to customary adjustment for levels of working capital. Up to $1.5 billion of the amount depends on the results of the COMBI-d trial. In the event of termination of transaction, GlaxoSmithKline has agreed to pay Novartis a termination ...
Read More


NOTA's price was unchanged after the transaction was announced on 04/22/14.
Investor / Buyer
Novartis AG
Creditor / Lender
GlaxoSmithKline plc
 
Announced 04/22/14
7.05B for Novartis AG, Global Vaccines Business
Merger/Acquisition

GlaxoSmithKline plc (LSE:GSK) entered into a share and business sale agreement to acquire global Vaccines business from Novartis AG (SWX:NOVN) for $7.1 billion on April 22, 2014. Under the terms of the agreement, Glaxo agreed to pay $5.25 billion at closing with subsequent potential milestone payments and ongoing royalties, including $450 million upon FDA regulatory approval for Novartis' MenABCWY vaccine product, $450 million in the event that Bexsero achieves an agreed ...
Read More


NOTA's price was unchanged after the transaction was announced on 04/22/14.
Investor / Buyer
GlaxoSmithKline plc
Creditor / Lender
Novartis AG
 
Announced 02/17/14
CoStim Pharmaceuticals Inc.
Merger/Acquisition

Novartis AG (SWX:NOVN) acquired CoStim Pharmaceuticals Inc. from Atlas Venture L.P. Partners, Innovation Fund, MPM Capital and others on February 17, 2014.


NOTA's price was unchanged after the transaction was announced on 02/17/14.
Investor / Buyer
Novartis AG
Creditor / Lender
Atlas Venture L.P.
MPM Capital
Partners Innovation Fund
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOTA:GR €65.86 EUR +0.21

NOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.31 USD +0.42
Bayer AG €101.21 EUR 0.00
Gilead Sciences Inc $88.73 USD -0.21
Novo Nordisk A/S kr247.80 DKK 0.00
Procter & Gamble Co/The $81.16 USD -0.45
View Industry Companies
 

Industry Analysis

NOTA

Industry Average

Valuation NOTA Industry Range
Price/Earnings 22.8x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 24.8x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.